Beam Therapeutics Inc. (BEAM): Results of Operations and Financial Condition
Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Se
How this was made
The 30-second read
Why it matters
The filing combines (1) cash runway into mid-2029, (2) clinical execution milestones (first pivotal cohort dose for BEAM-302, dosing completion for BEACON risto-cel), and (3) regulatory progress (FDA IND clearance for BEAM-304), plus (4) a stated expectation for risto-cel BLA submission by year-end 2026.
Market read
Traders can use this update to reassess near-term probability-weighted timelines for BEAM-302 pivotal execution, ERS catalyst timing, and risto-cel BLA submission, while monitoring cash burn and dilution risk.
What to watch
Cash runway extends to mid-2029, but dilution risk and trial execution risk remain, especially if pivotal enrollment or BLA preparation slips beyond the stated year-end 2026 window.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and program updates across Beam’s base-editing pipeline and hematology franchise.
Ticker impact
Beam reported Q2 2026 results, dosed the first patient in the BEAM-302 pivotal cohort, and said a risto-cel BLA is expected by year-end 2026.
Bullish bias with potential volatility into ERS Congress and around any updates to pivotal enrollment pace and BLA timing.
The filing adds multiple time-bound clinical and regulatory milestones (first pivotal dose, IND clearance, dosing completion, BLA timing) alongside cash runway into mid-2029, which can re-rate risk for a pre-revenue biotech.
Market effects
Reinforces investor focus on base-editing and LNP delivery platforms, with AATD and PKU programs adding incremental regulatory and clinical momentum.
Limited direct regional spillover; primary impact is on US-listed biotech sentiment.
ERS Congress late-breaking selection can draw international attention to AATD gene-editing progress.
Counterpoint
Milestones are progress updates, not efficacy readouts; without new efficacy endpoints, the market may fade the news after initial enthusiasm.
Key entities
- issuerBeam Therapeutics Inc.
Nasdaq-listed biotech advancing base editing and LNP delivery; reported Q2 2026 results and multiple clinical/regulatory milestones.
- clinical_programBEAM-302
Lead AATD program; first patient dosed in the global pivotal cohort and updated data selected for late-breaking oral presentation at ERS 2026.
- clinical_programBEAM-304
PKU program; FDA cleared the IND and Beam initiated Phase 1/2 start-up activities.
- clinical_programRisto-cel (ristoglogene autogetemcel)
Autologous cell therapy for sickle cell disease; dosing complete in BEACON and BLA expected as early as year-end 2026.
- financingSixth Street facility
Beam expects an additional $200 million draw to extend funding into mid-2029.
